Scholarly Index
Filipa Lynce
Dana-Farber Cancer Institute; 4,779 total citations; 200 total publications; best world rank #148
Dana-Farber Cancer Institute
4,779Total citations
200Total publications
29H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Advanced Breast Cancer Therapies | Lifetime | 632 | US 270 | 95.03 |
| PARP inhibition in cancer therapy | Lifetime | 847 | US 356 | 91.79 |
| Breast Cancer Treatment Studies | 2021-2025 | 148 | US 54 | 98.18 |
| HER2/EGFR in Cancer Research | 2021-2025 | 169 | US 59 | 97.46 |
| Advanced Breast Cancer Therapies | 2021-2025 | 157 | US 57 | 97.28 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 518 | US 168 | 92.78 |
| Cancer Treatment and Pharmacology | 2021-2025 | 303 | US 108 | 93.97 |
| PARP inhibition in cancer therapy | 2021-2025 | 255 | US 94 | 92.05 |
| BRCA gene mutations in cancer | 2021-2025 | 447 | US 209 | 89.25 |